Browse the evidence

There were no reported hospitalizations from severe hypoglycemia or diabetic ketoacidosis in the treated group.

The safety profile suggests that tirzepatide may be a safe option for managing T1D in this population.

There is a strong correlation between online search trends and prescriptions for semaglutide (Wegovy) with a correlation coefficient of r = 0.97.

Monitoring online search trends can provide insights into public interest in obesity medications.

Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased incidence of diabetic retinopathy (DR) with a hazard ratio (HR) of 1.07 (95% CI, 1.03-1.11).

Clinicians should be aware of the increased risk of DR when prescribing GLP-1 RAs to patients with T2D.

GLP-1 RAs are not associated with progression to proliferative diabetic retinopathy (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) in patients with preexisting DR.

Patients with preexisting DR may not experience worsening of certain complications when treated with GLP-1 RAs.

In patients with cardiometabolic HFpEF, semaglutide showed a 42% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Semaglutide may be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

There were no significant changes in testosterone and insulin-like growth factor 1 levels after the resistance training program.

Resistance training may not significantly affect testosterone and IGF-1 levels in older women.

GIP antagonism has been shown to reduce the development of obesity in preclinical models.

GIP antagonism could be a potential strategy for obesity treatment.

The effect of linolenic acid on food intake and body mass disappears in mice lacking the GDF15 receptor GFRAL.

The presence of the GFRAL receptor is essential for the appetite-suppressing effects of linolenic acid.

Manufacturer discounts for GLP1s approved for obesity were estimated at 41%, resulting in net prices of $717 to $761 per month of supply.

Practitioners should consider the significant discounts when discussing GLP1s with patients.

Manufacturer discounts for GLP1s approved for type 2 diabetes ranged from 54% to 59%, leading to net prices of $312 to $469 per month of supply.

Practitioners should be aware of the cost implications of GLP1s for type 2 diabetes when advising patients.

The magnitude of manufacturer discounts highlights the importance of considering net price information in coverage decision-making for GLP1s.

Healthcare decision-makers should factor in net prices when evaluating GLP1 coverage options.

The development of new uses and long-lasting preparations of GLP-1 drugs is crucial for future market potential.

Practitioners should stay informed about new formulations and uses of GLP-1 drugs to leverage their market potential.

Ex-DARPin fusion proteins injected at 25 nmol/kg every three days significantly lowered blood glucose, inhibited food consumption, and reduced body weight for 30 days in STZ-induced diabetic mice.

Ex-DARPin fusion proteins may be a promising treatment for managing blood glucose and weight in diabetic patients.

Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, offer substantial potential due to their oral bioavailability and favorable gastrointestinal tolerability.

Practitioners may consider these candidates for their potential benefits in treatment regimens.

GLP-1RAs probably have little or no effect on risk for thyroid cancer.

Practitioners should consider that GLP-1RAs may not significantly increase thyroid cancer risk based on current evidence.

GLP-1RAs may have little or no effect on pancreatic cancer risk.

Practitioners should be aware that GLP-1RAs may not significantly increase pancreatic cancer risk.

The use of GLP-1RA medications has been associated with increased hypoglycaemia risk in patients treated with concomitant antihyperglycaemic medications.

Clinicians should monitor for hypoglycaemia when initiating GLP-1RA therapy in patients on other antihyperglycaemic medications.

Further study is needed to understand GIP's implications on weight reduction and other diseases.

Practitioners should be aware of the potential broader implications of GIP therapies.

The number of incident GLP-1 RA users in France increased from 5117 in January 2017 to 15,193 in June 2023.

Healthcare providers should be aware of the significant increase in GLP-1 RA prescriptions.

Continuation of GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents during EGD.

Practitioners can consider continuing GLP-1RAs during EGD without increased risk of residual gastric contents.

The study highlights a persistently elevated pulmonary aspiration risk in patients receiving semaglutide.

Anesthesiologists should be cautious of the increased aspiration risk in patients on semaglutide during surgery.

GLP-1 receptor-based agonists and oral dipeptidyl peptidase-4 inhibitors are currently the only available treatments for metabolic diseases.

Practitioners should be aware that current treatment options are limited to GLP-1 receptor-based therapies.

Current GLP-1-based therapies face challenges such as high costs and the need for repeated administration.

Healthcare providers should consider these challenges when prescribing GLP-1 therapies.

Plasma GLP-1 and PYY responses do not differ between individuals with obesity and lean controls.

This suggests that obesity does not affect the immediate hormonal response of GLP-1 and PYY to a meal.